SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: brent gephart who wrote (394)9/16/1998 1:21:00 PM
From: growthvalue  Read Replies (3) | Respond to of 586
 
Wow, thanks. Actually, I have another question regarding prosorba - is this a disposable device and/or is it used in conjunction with a machine?

I am floored - this really looks like a fantastic product. And this is the first I've heard of it.

GV



To: brent gephart who wrote (394)9/16/1998 1:44:00 PM
From: dwight martin  Read Replies (1) | Respond to of 586
 
"Yes. From Cypresses Annual report they say that "over 10% of RA sufferers are expected to fail conventional therapies." With over 200,000 new patients being diagnosed each year."

This 10% figure does not encompass the new drugs (Enbrel? Arava?), does it?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News